.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Teva
Merck
QuintilesIMS
Medtronic
Cerilliant
US Department of Justice
Julphar
Harvard Business School
Covington

Generated: December 16, 2017

DrugPatentWatch Database Preview

ARICEPT ODT Drug Profile

« Back to Dashboard

Which patents cover Aricept Odt, and when can generic versions of Aricept Odt launch?

Aricept Odt is a drug marketed by Eisai Inc and is included in one NDA.

The generic ingredient in ARICEPT ODT is donepezil hydrochloride. There are thirty-one drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai IncARICEPT ODTdonepezil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021720-001Oct 18, 2004ABRXYesNo► Subscribe► Subscribe► Subscribe
Eisai IncARICEPT ODTdonepezil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021720-002Oct 18, 2004ABRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ARICEPT ODT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai IncARICEPT ODTdonepezil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021720-001Oct 18, 2004► Subscribe► Subscribe
Eisai IncARICEPT ODTdonepezil hydrochlorideTABLET, ORALLY DISINTEGRATING;ORAL021720-002Oct 18, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ARICEPT ODT

Drugname Dosage Strength RLD Submissiondate
donepezil hydrochlorideOrally Disintegrating Tablets5 mg and 10 mgAricept ODT6/30/2010

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Johnson and Johnson
Dow
McKesson
Queensland Health
Argus Health
Accenture
Federal Trade Commission
Chubb
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot